{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:41:06Z","timestamp":1790905266129,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jns.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T13:30:30Z","timestamp":1557235830000},"page":"12-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis"],"prefix":"10.1016","volume":"402","author":[{"given":"Yukiko","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manato","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2019.05.003_bb0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135245850000600408","article-title":"A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations","volume":"6","author":"Miller","year":"2000","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2019.05.003_bb0015","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458515617248","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2019.05.003_bb0020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11940-013-0242-9","article-title":"Neurosarcoidosis","volume":"15","author":"Nozaki","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0025","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","article-title":"Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis","volume":"68","author":"Komiyama","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2019.05.003_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2019.05.003_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2019.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jns.2019.05.003_bb0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2019.05.003_bb0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11940-005-0009-z","article-title":"Ocular myasthenia gravis","volume":"7","author":"Porter","year":"2005","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0060","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2019.05.003_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cen3.12091","article-title":"Clinical features and treatment status of adult myasthenia gravis in Japan","volume":"5","author":"Murai","year":"2014","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.jns.2019.05.003_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneur.57.5.752","article-title":"Treatment of ocular myasthenia: steroids only when compelled","volume":"57","author":"Kaminski","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2019.05.003_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.jns.2019.05.003_bb0090","first-page":"285","article-title":"Three cases of myasthenia gravis treated effectively with high-dose intravenous methylprednisolone pulse therapy for the extraocular muscle paralysis","volume":"32","author":"Fukumoto","year":"2015","journal-title":"Neuro-Ophthalmol. Japan"},{"key":"10.1016\/j.jns.2019.05.003_bb0095","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19302114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X19302114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T19:12:21Z","timestamp":1560366741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X19302114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":19,"alternative-id":["S0022510X19302114"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2019.05.003","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}